Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 1375

Sort by

Sort Order Select

Journal Articles

HIV infection is associated with compromised tumor microenvironment adaptive immune reactivity in Hodgkin lymphoma

Amanda Chantziou, Cloe Brenna, Kalliopi Ioannidou, Oliver Y. Chen, Penelope Korkolopoulou, Anastasia Antoniadou, Mina Psichogiou, Maria Papaioannou, Panagiotis Tsirigotis, Periklis G. Foukas, Laurence de Leval, Constantinos Petrovas

Blood Adv (2024) 8 (24): 6215–6231.

https://doi.org/10.1182/bloodadvances.2023012116

Published: 2024

Includes: Supplemental data

Journal Articles

Evolving consolidation patterns and outcomes for a large cohort of patients with primary CNS lymphoma

Kathryn R. Tringale, Michael Scordo, Joachim Yahalom, Charlie White, Zhigang Zhang, Javin Schefflein, Gustav Cederquist, Lauren R. Schaff, Lisa DeAngelis, Brandon S. Imber, Christian Grommes

Blood Adv (2024) 8 (24): 6195–6206.

https://doi.org/10.1182/bloodadvances.2024013780

Published: 2024

Includes: Supplemental data

Journal Articles

Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration

Nektarios Kostopoulos, Francesca Costabile, Elisavet Krimitza, Silvia Beghi, Denisa Goia, Renzo Perales-Linares, George Thyfronitis, Michael J. LaRiviere, Elise A. Chong, Stephen J. Schuster, Amit Maity, Constantinos Koumenis, John P. Plastaras, Andrea Facciabene

Blood Adv (2024) 8 (24): 6308–6320.

https://doi.org/10.1182/bloodadvances.2024012599

Published: 2024

Includes: Supplemental data

Journal Articles

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas

Blood Adv (2024) 8 (24): 6268–6281.

https://doi.org/10.1182/bloodadvances.2023012291

Published: 2024

Includes: Supplemental data

Journal Articles

Cardiovascular toxicities associated with novel cellular immune therapies

Malak Munir, Ahmed Sayed, Daniel Addison, Narendranath Epperla

Blood Adv (2024) 8 (24): 6282–6296.

https://doi.org/10.1182/bloodadvances.2024013849

Published: 2024

Journal Articles

Incidence of preexisting B-cell aplasia in B-ALL: implications for post–CAR T-cell monitoring

Isha Sahai, Paul Borgman, Bonnie Yates, Sergio Rosenzweig, Shakuntala Rampertaap, Alexander W. Rankin, Nirali N. Shah

Blood Adv (2024) 8 (24): 6329–6333.

https://doi.org/10.1182/bloodadvances.2024014641

Published: 2024

Journal Articles

Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes

Blood Adv (2024) 8 (24): 6297–6307.

https://doi.org/10.1182/bloodadvances.2024013327

Published: 2024

Includes: Supplemental data

Journal Articles

Retreatment of multiple myeloma with previously refractory drugs

Blood Adv (2024) 8 (24): 6321–6328.

https://doi.org/10.1182/bloodadvances.2024014723

Published: 2024

Includes: Supplemental data

Journal Articles

Time to revisit reduced-dose radiotherapy for PCNSL?

Maciej Tatarczuch

Blood Adv (2024) 8 (24): 6234–6236.

https://doi.org/10.1182/bloodadvances.2024014588

Published: 2024

Journal Articles

Fusion-specific chromatin profiles mediate transcriptional heterogeneity in MLL-rearranged acute lymphoblastic leukemia

Shan Lin, Michael Kotliar, Sushmitha Vallabh, Anetta Ptasinska, Salam a Assi, Mark Wunderlich, Constanze Bonifer, Artem Barski, James C Mulloy

Blood Adv bloodadvances.2024014065.

https://doi.org/10.1182/bloodadvances.2024014065

Published: 2024

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study

Blood Adv bloodadvances.2024014903.

https://doi.org/10.1182/bloodadvances.2024014903

Published: 2024

Includes: Supplemental data

Journal Articles

Point-of-care CAR T manufacturing solutions: can 1 model fit all?

Álvaro Urbano-Ispizua, Nirav N. Shah, Natasha Kekre

Blood Adv (2024) 8 (23): 6133–6136.

https://doi.org/10.1182/bloodadvances.2024012982

Published: 2024

Journal Articles

Impact of prior treatment on CAR T-cell outcome in adult ALL

David I. Marks, Anna Z. Castleton

Blood Adv (2024) 8 (23): 6137–6138.

https://doi.org/10.1182/bloodadvances.2024014237

Published: 2024

Journal Articles

Charting the course for CAR T-cell manufacturing

Magdi Elsallab, Marcela V. Maus

Blood Adv (2024) 8 (23): 6131–6132.

https://doi.org/10.1182/bloodadvances.2024014653

Published: 2024

Journal Articles

Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL

Ibrahim Aldoss, Gregory W. Roloff, Rawan Faramand, Noam E. Kopmar, Chenyu Lin, Anjali S. Advani, Simone E. Dekker, Vishal K. Gupta, Timothy E. O'Connor, Nikeshan Jeyakumar, Ibrahim N. Muhsen, Yannis Valtis, Amy Zhang, Katharine Miller, Katherine Sutherland, Kaitlyn C. Dykes, Mohamed Ahmed, Evan Chen, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Bhagirathbhai Dholaria, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shahbaz A. Malik, John Mathews, Paul Shaughnessy, Aaron C. Logan, Abdullah Ladha, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Matthew Connor, Kristen M. O'Dwyer, LaQuisa C. Hill, Stephanie B. Tsai, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Caspian Oliai, Jessica T. Leonard, Noelle V. Frey, Jae H. Park, Marlise R. Luskin, Veronika Bachanova, Ahmed Galal, Michael R. Bishop, Wendy Stock, Ryan D. Cassaday, Vinod Pullarkat, Bijal D. Shah, Lori S. Muffly

Blood Adv (2024) 8 (23): 6139–6147.

https://doi.org/10.1182/bloodadvances.2024013747

Published: 2024

Includes: Supplemental data

Journal Articles

Genetic Disruption of Blimp-1 Drastically Augments the Antitumor Efficacy of BCMA-Targeting CAR-T Cells

Anthony M Battram, Joan Mañé Pujol, David F Moreno, Aina Oliver-Caldes, Judit Carpio, Oriol Cardus, Luis Gerardo Rodríguez-Lobato, Álvaro Urbano-Ispizua, Carlos Fernández de Larrea

Blood Adv bloodadvances.2024013209.

https://doi.org/10.1182/bloodadvances.2024013209

Published: 2024

Includes: Supplemental data

Journal Articles

New Strategies for Enhancing Enrollment of Underrepresented Minorites in Lymphoma Clinical Trials

Chijioke Nze, Alex F. Herrera

Blood Adv bloodadvances.2024012981.

https://doi.org/10.1182/bloodadvances.2024012981

Published: 2024

Journal Articles

OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL

Blood Adv (2024) 8 (23): 6114–6126.

https://doi.org/10.1182/bloodadvances.2024013254

Published: 2024

Includes: Supplemental data

Journal Articles

Treatment Patterns and Outcomes in Follicular Lymphoma with POD24: An Analysis from The LEO Consortium

Blood Adv bloodadvances.2024014053.

https://doi.org/10.1182/bloodadvances.2024014053

Published: 2024

Includes: Supplemental data

Journal Articles

Genomic landscape of testicular follicular lymphoma is characterized by frequent 1p36/TNFRSF14 alterations

Weiwei Zhang, Anamarija M Perry, Hans Magne Hamnvåg, Sumire Kitahara, Sarah L. Ondrejka, Alexandra E Kovach, Ji (Jane) Yuan, Krystie Chew, Julia Hsueh Davidson, Victoria Bedell, Jamie Stokke, Joo Y Song

Blood Adv bloodadvances.2024014002.

https://doi.org/10.1182/bloodadvances.2024014002

Published: 2024

Includes: Supplemental data

NARROW

HIV infection is associated with compromised tumor microenvironment adaptive immune reactivity in Hodgkin lymphoma

Evolving consolidation patterns and outcomes for a large cohort of patients with primary CNS lymphoma

Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration

PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas

Cardiovascular toxicities associated with novel cellular immune therapies

Incidence of preexisting B-cell aplasia in B-ALL: implications for post–CAR T-cell monitoring

Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes

Retreatment of multiple myeloma with previously refractory drugs

Time to revisit reduced-dose radiotherapy for PCNSL?

Fusion-specific chromatin profiles mediate transcriptional heterogeneity in MLL-rearranged acute lymphoblastic leukemia

Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study

Point-of-care CAR T manufacturing solutions: can 1 model fit all?

Impact of prior treatment on CAR T-cell outcome in adult ALL

Charting the course for CAR T-cell manufacturing

Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL

Genetic Disruption of Blimp-1 Drastically Augments the Antitumor Efficacy of BCMA-Targeting CAR-T Cells

New Strategies for Enhancing Enrollment of Underrepresented Minorites in Lymphoma Clinical Trials

OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL

Treatment Patterns and Outcomes in Follicular Lymphoma with POD24: An Analysis from The LEO Consortium

Genomic landscape of testicular follicular lymphoma is characterized by frequent 1p36/TNFRSF14 alterations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only